Solventum Co. (NYSE:SOLV) Stock Holdings Trimmed by Bank of Montreal Can

Bank of Montreal Can trimmed its stake in Solventum Co. (NYSE:SOLV - Free Report) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 177,950 shares of the company's stock after selling 4,798 shares during the quarter. Bank of Montreal Can owned about 0.10% of Solventum worth $11,755,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of SOLV. Modus Advisors LLC acquired a new stake in shares of Solventum during the 4th quarter worth $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum in the 4th quarter worth about $26,000. Crews Bank & Trust acquired a new position in shares of Solventum in the 4th quarter valued at about $32,000. Synergy Asset Management LLC purchased a new stake in shares of Solventum during the 4th quarter worth about $35,000. Finally, Spire Wealth Management acquired a new stake in Solventum during the 4th quarter worth approximately $37,000.

Solventum Stock Up 0.8 %

SOLV stock traded up $0.56 during midday trading on Friday, hitting $66.23. 910,263 shares of the company's stock were exchanged, compared to its average volume of 1,325,909. The firm has a 50 day moving average price of $73.56 and a 200-day moving average price of $71.62. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The stock has a market capitalization of $11.46 billion and a price-to-earnings ratio of 24.08. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Analyst Ratings Changes

A number of research analysts have weighed in on SOLV shares. Bank of America lifted their price target on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Wednesday, February 26th. The Goldman Sachs Group upped their price target on shares of Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research report on Monday, March 3rd. Wells Fargo & Company raised their price objective on Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. Piper Sandler boosted their price objective on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Finally, Morgan Stanley increased their target price on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.